etoposide has been researched along with Esthesioneuroblastoma, Olfactory in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedi, P; Chaukar, DA; Ghosh Laskar, S; Kumar Singh, A; Menon, N; Noronha, V; Pai, PS; Patil, VM; Patlekar, G; Prabhash, K; Saha, S; Yadav, N | 1 |
| Bhandari, R; Jat, B; Kumar, P; Sehrawat, A; Singh, A; Sundriyal, D | 1 |
| Bell, D; Ferrarotto, R; Frank, SJ; Fuller, CD; Glisson, BS; Gunn, GB; Hanna, EY; Kies, MS; Kupferman, ME; Phan, J; Roberts, D; Su, SY | 1 |
| Busse, PM; Ebb, DH; Friedmann, AM; Ladra, MM; Lucas, JT; MacDonald, SM; Marcus, KJ; Tarbell, NJ; Yock, TI | 1 |
| Bhattacharjee, A; Chaturvedi, P; D'Cruz, A; Dhumal, S; Joshi, A; Kane, S; Noronha, V; Pai, P; Patil, VM; Prabhash, K; Sharma, V; Zanwar, S | 1 |
| Bridger, GP; Broadley, K; Meagher, NS; Smee, RI; Williams, JR | 1 |
| Amdur, RJ; Hinerman, RW; Mendenhall, WM; Monroe, AT; Morris, CG | 1 |
| Hatake, K; Irie, T; Ito, Y; Kamata, S; Kawabata, K; Mishima, Y; Nagasaki, E; Oguchi, M; Takahashi, S; Terui, Y | 1 |
| Bang, YJ; Heo, DS; Jo, YH; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, CH; Rhee, CS; Wu, HG | 1 |
| Constantinidis, J; Dimmler, A; Iro, H; Koch, M; Strauss, C | 1 |
| Bouissou, F; Chancholle, A; Claeyssens, S; Fabre, J; Robert, A; Rubie, H; Tscherning, C | 1 |
| Amrein, PC; Bhattacharyya, N; Goodman, ML; Joseph, MP; Thornton, AF | 1 |
| Buckner, JC; Lewis, JE; McElroy, EA | 1 |
| Eisele, DW; Forastiere, A; Lee, DJ; Resto, VA; Westra, WH; Zahurak, M | 1 |
| Mineta, H; Miura, K; Tsutsui, Y; Yokota, N | 1 |
1 review(s) available for etoposide and Esthesioneuroblastoma, Olfactory
| Article | Year |
|---|---|
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Mesna; Methotrexate; Middle Aged; Mitomycin; Nasal Cavity; Nose Neoplasms; Paranasal Sinus Neoplasms; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
14 other study(ies) available for etoposide and Esthesioneuroblastoma, Olfactory
| Article | Year |
|---|---|
Real world data on long term outcome of neoadjuvant chemotherapy in locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation - Results from a single centre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Esthesioneuroblastoma, Olfactory; Etoposide; Humans; Middle Aged; Nasal Cavity; Neoadjuvant Therapy; Nose Neoplasms; Paranasal Sinus Neoplasms; Retrospective Studies; Young Adult | 2023 |
Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Beauty; Cisplatin; Depression; Diagnosis, Differential; Esthesioneuroblastoma, Olfactory; Etoposide; Face; Female; Humans; Magnetic Resonance Imaging; Nasal Cavity; Nasal Surgical Procedures; Neoadjuvant Therapy; Nose Deformities, Acquired; Nose Neoplasms; Treatment Outcome | 2021 |
Outcomes for olfactory neuroblastoma treated with induction chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined Modality Therapy; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Induction Chemotherapy; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Analysis; Young Adult | 2017 |
Proton therapy for pediatric and adolescent esthesioneuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Nasal Cavity; Nose Neoplasms; Proton Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Retrospective Studies; Topotecan; Treatment Outcome; Vincristine; Young Adult | 2015 |
Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Cohort Studies; Disease-Free Survival; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Follow-Up Studies; Humans; Male; Nasal Cavity; Nausea; Neoadjuvant Therapy; Neuroendocrine Tumors; Palliative Care; Paranasal Sinus Neoplasms; Survival Rate; Treatment Outcome | 2016 |
Retained role of surgery for olfactory neuroblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Audit; Clinical Protocols; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Male; Middle Aged; Nasal Cavity; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nose Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Young Adult | 2011 |
Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blindness; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Cytarabine; Epirubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Nasal Cavity; Necrosis; Neoplasm Recurrence, Local; Nose Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Salvage Therapy; Spinal Cord Neoplasms; Survival Analysis | 2003 |
Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nose Neoplasms; Retrospective Studies; Vincristine | 2004 |
Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Ifosfamide; Immunohistochemistry; Male; Middle Aged; Nasal Cavity; Neoadjuvant Therapy; Nose Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
[Long-term experiences in the therapy of esthesioneuroblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Dactinomycin; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Nasal Cavity; Neoplasm Staging; Nose Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Time Factors; Vincristine | 2006 |
Recurrent renal salt wasting in a child treated with carboplatin and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Brain Neoplasms; Carboplatin; Child, Preschool; Esthesioneuroblastoma, Olfactory; Etoposide; Humans; Hyponatremia; Kidney Tubules, Proximal; Male; Recurrence; Sodium | 1994 |
Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Paranasal Sinus Neoplasms; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 1997 |
Esthesioneuroblastoma: the Johns Hopkins experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nasal Cavity; Neoplasm Staging; Nose Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies | 2000 |
Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Transformation, Neoplastic; Combined Modality Therapy; Esthesioneuroblastoma, Olfactory; Etoposide; Fatal Outcome; Ganglioneuroma; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Nasal Cavity; Nose Neoplasms; Radiotherapy, Adjuvant | 2001 |